Published Date: February 13, 2021

Full Text Article

<em>CRB1</em>-associated retinal dystrophies in a Belgian cohort: genetic characteristics and long-term clinical follow-up

Authors: Mays Talib, Caroline Van Cauwenbergh, Julie De Zaeytijd, David Van Wynsberghe, Elfride De Baere, Camiel J F Boon, Bart Peter Leroy

Br J Ophthalmol. 2022 May;106(5):696-704. doi: 10.1136/bjophthalmol-2020-316781. Epub 2021 Feb 12.


AIM: To investigate the natural history in a Belgian cohort of CRB1-associated retinal dystrophies.

METHODS: An in-depth retrospective study focusing on visual function and retinal structure.

RESULTS: Forty patients from 35 families were included (ages: 2.5-80.1 years). In patients with a follow-up of >1 year (63%), the mean follow-up time was 12.0 years (range: 2.3-29.2 years). Based on the patient history, symptoms and/or electroretinography, 22 patients (55%) were diagnosed with retinitis pigmentosa (RP), 15 (38%) with Leber congenital amaurosis (LCA) and 3 (8%) with macular dystrophy (MD), the latter being associated with the p.(Ile167_Gly169del) mutation (in compound heterozygosity). MD later developed into a rod-cone dystrophy in one patient. Blindness at initial presentation was seen in the first decade of life in LCA, and in the fifth decade of life in RP. Eventually, 28 patients (70%) reached visual acuity-based blindness (<0.05). Visual field-based blindness (<10°) was documented in 17/25 patients (68%). Five patients (13%) developed Coats-like exudative vasculopathy. Intermediate/posterior uveitis was found in three patients (8%). Cystoid maculopathy was common in RP (9/21; 43%) and MD (3/3; 100%). Macular involvement, varying from retinal pigment epithelium alterations to complete outer retinal atrophy, was observed in all patients.

CONCLUSION: Bi-allelic CRB1 mutations result in a range of progressive retinal disorders, most of which are generalised, with characteristically early macular involvement. Visual function and retinal structure analysis indicates a window for potential intervention with gene therapy before the fourth decade of life in RP and the first decade in LCA.

PMID: 33579689DOI: 10.1136/bjophthalmol-2020-316781